Consensus-based recommendations on cilostazol and standardized Ginkgo biloba combination therapy for secondary stroke prevention and post-stroke cognitive impairment (PSCI) management

Objective: Post-stroke cognitive impairment (PSCI), particularly in patients with cerebral small vessel disease (SVD), remains an important challenge. This Korean NeuroEndovascular Society (KoNES) expert consensus evaluates the rationale for combining cilostazol with standardized Ginkgo biloba extract to address vascular and cognitive aspects of post-stroke care. Methods: An expert panel formulated clinical questions and reviewed randomized trials, meta-analyses, and translational evidence. Recommendations were refined through iterative discussion and review, considering clinical applicability in South Korea. Results: Cilostazol reduces recurrent ischemic stroke risk with a relatively low risk of hemorrhagic complications and may slow white matter lesion progression. Standardized Ginkgo biloba extract, particularly EGb 761, has shown cognitive and functional benefits in selected populations. A standardized extract used in Korea has a broadly similar phytochemical composition, but direct comparative bioequivalence data are lacking. Available pharmacological and clinical evidence suggests complementary mechanisms for the combination, without a clear bleeding signal under studied conditions. Nevertheless, direct evidence of efficacy and safety for combined treatment in stroke populations is limited. Fixed-dose combinations may reduce pill burden when both treatments are indicated. Conclusions: Combining cilostazol with standardized Ginkgo biloba extract may offer a multi-target approach for stroke survivors with SVD or PSCI. Its clinical use should acknowledge the limitations of indirect evidence; prospective randomized trials are needed to establish long-term efficacy and safety.

Authors

Institutions

Publication Details

Journal
Journal of Cerebrovascular and Endovascular Neurosurgery
Published
2026-11-19
DOI
https://doi.org/10.7461/jcen.2026.e2026.08.007
Primary Topic
Ginkgo biloba and Cashew Applications
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Consensus-based recommendations on cilostazol and standardized Ginkgo biloba combination therapy for secondary stroke prevention and post-stroke cognitive impairment (PSCI) management

Joonho Chung, Jung Cheol Park, Seung Hun Sheen, Sung-Kon Ha et al.
2 links
Journal of Cerebrovascular and Endovascular Neurosurgery
Ginkgo biloba and Cashew Applications
article

Consensus-based recommendations on cilostazol and standardized Ginkgo biloba combination therapy for secondary stroke prevention and post-stroke cognitive impairment (PSCI) management

Joonho Chung, Jung Cheol Park, Seung Hun Sheen, Sung-Kon Ha, Keun Young Park, Won Ki Yoon, Sukh Que Park, Young Woo Kim, Dong-Seong Shin, Hoon Kim, Jae Hyung Choi, Jae Sang Oh, Dong Young Cho, Jong Young Lee
article en

Abstract

Objective: Post-stroke cognitive impairment (PSCI), particularly in patients with cerebral small vessel disease (SVD), remains an important challenge. This Korean NeuroEndovascular Society (KoNES) expert consensus evaluates the rationale for combining cilostazol with standardized Ginkgo biloba extract to address vascular and cognitive aspects of post-stroke care. Methods: An expert panel formulated clinical questions and reviewed randomized trials, meta-analyses, and translational evidence. Recommendations were refined through iterative discussion and review, considering clinical applicability in South Korea. Results: Cilostazol reduces recurrent ischemic stroke risk with a relatively low risk of hemorrhagic complications and may slow white matter lesion progression. Standardized Ginkgo biloba extract, particularly EGb 761, has shown cognitive and functional benefits in selected populations. A standardized extract used in Korea has a broadly similar phytochemical composition, but direct comparative bioequivalence data are lacking. Available pharmacological and clinical evidence suggests complementary mechanisms for the combination, without a clear bleeding signal under studied conditions. Nevertheless, direct evidence of efficacy and safety for combined treatment in stroke populations is limited. Fixed-dose combinations may reduce pill burden when both treatments are indicated. Conclusions: Combining cilostazol with standardized Ginkgo biloba extract may offer a multi-target approach for stroke survivors with SVD or PSCI. Its clinical use should acknowledge the limitations of indirect evidence; prospective randomized trials are needed to establish long-term efficacy and safety.

Journal of Cerebrovascular and Endovascular Neurosurgery
Ewha Womans University (KR), Hallym University (KR), Yonsei University (KR), Korea University (KR), Soonchunhyang University (KR), Severance Hospital (KR), Korea University Medical Center (KR), Dong-A University Hospital (KR), Soonchunhyang University Hospital Seoul (KR), Asan Medical Center (KR), University of Ulsan (KR), The Catholic University of Korea Uijeongbu St. Mary's Hospital (KR), CHA University Bundang Medical Center (KR), Kangdong Sacred Heart Hospital (KR), CHA University (KR), Korea University (JP), Soonchunhyang University Hospital Bucheon (KR), Korea University Guro Hospital (KR), Pohang Medical Center (KR), Ewha Womans University Seoul Hospital (KR), Korea University Ansan Hospital (KR), Dong-A University (KR), Bucheon University (KR), Catholic University of Korea (KR)
Good health and well-being
Ginkgo biloba and Cashew Applications
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon